akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Company profile
Ticker
AKRO
Exchange
Website
CEO
Andrew Cheng
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Akero Securities Corporation ...
AKRO stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Unregistered Sales of Equity Securities
18 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
424B5
Prospectus supplement for primary offering
6 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
8-K
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
4 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
18 Dec 23
Latest ownership filings
4
Jonathan Young
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Catriona Yale
15 Mar 24
4
William Richard White
15 Mar 24
4
Andrew Cheng
15 Mar 24
4
Jonathan Young
15 Mar 24
4
Timothy Rolph
15 Mar 24
SC 13G
GENERAL ATLANTIC, L.P.
15 Mar 24
4
Andrew Cheng
6 Mar 24
4
Catriona Yale
6 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 269.55 mm | 269.55 mm | 269.55 mm | 269.55 mm | 269.55 mm | 269.55 mm |
Cash burn (monthly) | 58.20 mm | 8.71 mm | 15.54 mm | 11.37 mm | 16.57 mm | 10.19 mm |
Cash used (since last report) | 400.17 mm | 59.91 mm | 106.83 mm | 78.16 mm | 113.95 mm | 70.04 mm |
Cash remaining | -130.63 mm | 209.64 mm | 162.71 mm | 191.39 mm | 155.60 mm | 199.50 mm |
Runway (months of cash) | -2.2 | 24.1 | 10.5 | 16.8 | 9.4 | 19.6 |
Institutional ownership, Q2 2022
70.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 121 |
Opened positions | 24 |
Closed positions | 11 |
Increased positions | 40 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 1.18 bn |
Total shares | 49.06 mm |
Total puts | 0.00 |
Total calls | 11.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Skorpios Trust | 4.91 mm | $46.38 mm |
JHG Janus Henderson | 3.07 mm | $28.99 mm |
venBio Global Strategic Fund | 3.03 mm | $106.05 mm |
Alkeon Capital Management | 2.62 mm | $24.76 mm |
PFE Pfizer | 2.53 mm | $30.71 mm |
venBio Global Strategic Fund II | 2.32 mm | $67.76 mm |
Point72 Asset Management | 2.30 mm | $21.74 mm |
Atlas Venture Life Science Advisors | 2.23 mm | $21.10 mm |
venBio Partners | 2.17 mm | $20.52 mm |
BLK Blackrock | 2.09 mm | $19.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Young Jonathan | Common Stoek | Sell | Dispose S | No | Yes | 25.025 | 400 | 10.01 k | 263,306 |
1 Apr 24 | Young Jonathan | Common Stock | Sell | Dispose S | No | Yes | 24.3267 | 4,600 | 111.90 k | 263,706 |
13 Mar 24 | William Richard White | Common Stock | Sell | Dispose S | No | No | 28.33 | 724 | 20.51 k | 49,630 |
13 Mar 24 | Cheng Andrew | Common Stock | Sell | Dispose S | No | No | 28.33 | 1,969 | 55.78 k | 589,447 |
13 Mar 24 | Catriona Yale | Common Stock | Sell | Dispose S | No | No | 28.33 | 723 | 20.48 k | 77,692 |
13 Mar 24 | Rolph Timothy | Common Stock | Sell | Dispose S | No | No | 28.33 | 619 | 17.54 k | 182,558 |
News
Akero Therapeutics Publishes Phase 2b SYMMETRY Cohort D Study In Clinical Gastroenterology And Hepatology
7 Mar 24
Akero Therapeutics Prices Public Offering Of 11M Common Stock At $29/Share
6 Mar 24
UBS Maintains Buy on Akero Therapeutics, Raises Price Target to $42
5 Mar 24
HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $50
5 Mar 24
Akero Therapeutics Begins Public Offering Of $300M Of Shares Of Its Common Stock
4 Mar 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
20 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
16 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
8 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
4 Apr 24